Product image of MYQORZO (aficamten) (Aficamten) 5 mg/1 TABLET, FILM COATED supplied by GNH India

MYQORZO (aficamten)

Active Ingredient:
Aficamten
Form:
TABLET, FILM COATED
Brand:
MYQORZO
Origin:
USA

MYQORZO (aficamten) (Aficamten TABLET, FILM COATED) 5 mg/1

MYQORZO (aficamten) is an FDA-approved oral cardiac myosin inhibitor developed by Cytokinetics, Inc. for treating obstructive hypertrophic cardiomyopathy (OHCM). Designated as an orphan drug, it represents a novel therapeutic approach in cardiology by directly targeting the underlying pathophysiology of this rare genetic heart condition.

Strength

5 mg/1

Pack Size

30 TABLET, FILM COATED in 1 BOTTLE (82112-105-30)

Manufacturer / TM Owner

Cytokinetics, Inc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

  • MYQORZO is indicated for the treatment of obstructive hypertrophic cardiomyopathy (OHCM) in adult patients. OHCM is a genetic disorder characterized by abnormal thickening of the heart muscle, leading to obstruction of blood flow from the left ventricle and resulting in symptoms such as dyspnea, chest pain, syncope, and exercise intolerance. MYQORZO works as a cardiac myosin inhibitor, reducing the force generated by cardiac muscle contractions and thereby decreasing left ventricular outflow tract obstruction. The drug targets symptomatic patients who remain limited despite optimal medical therapy or who are intolerant to existing treatments. By modulating the fundamental contractile mechanism of the heart, aficamten addresses the pathophysiologic basis of OHCM, offering a mechanistically distinct option from traditional beta-blockers, calcium channel blockers, and disopyramide used in this patient population.

Side Effects

  • Common adverse effects of MYQORZO include dizziness, dyspnea, fatigue, and syncope. Serious adverse events include worsening heart failure, hypotension, and cardiac arrhythmias. Patients require baseline and periodic cardiac monitoring including echocardiography and electrocardiography to assess left ventricular function and outflow tract obstruction. Regular blood pressure monitoring is essential due to hypotensive effects. Laboratory monitoring should include assessment of cardiac biomarkers and renal function. Dose adjustments may be necessary based on clinical response and tolerability. Patients should be counseled on symptom recognition and instructed to report signs of decompensation immediately.

Precautions & Warnings

  • MYQORZO is contraindicated in patients with severe systolic dysfunction or acute decompensated heart failure. Caution is warranted in patients with hypotension, renal impairment, or hepatic dysfunction, as dose adjustments may be required. Pregnancy category data should be reviewed with healthcare providers, as limited safety data exist in pregnant women. Pediatric use has not been established. Patients with baseline QT prolongation require careful monitoring. Concurrent use with other negative inotropic agents requires careful consideration. Regular assessment of left ventricular ejection fraction is mandatory to detect potential deterioration in systolic function during therapy.

Avoid Interactions

  • MYQORZO may interact with medications affecting cardiac contractility, including beta-blockers, calcium channel blockers, and antiarrhythmic agents; dose adjustments may be necessary. Strong CYP3A4 inhibitors may increase aficamten concentrations and require dose reduction. Concurrent use with other myosin inhibitors is not recommended. NSAIDs and ACE inhibitors may potentiate hypotensive effects. Patients should avoid grapefruit juice, which may inhibit CYP3A4 metabolism. Consultation with healthcare providers regarding all concurrent medications is essential.

Frequently Asked Questions

MYQORZO is used to treat obstructive hypertrophic cardiomyopathy (OHCM) in adults. It works by inhibiting cardiac myosin, reducing the force of heart muscle contractions and decreasing the obstruction of blood flow from the left ventricle. This helps alleviate symptoms such as shortness of breath, chest pain, and fainting.

MYQORZO is administered orally as a tablet. The dosing regimen is individualized based on patient tolerance and clinical response, with dose titration typically occurring over several weeks. Patients should take MYQORZO exactly as prescribed by their healthcare provider.

Common side effects include dizziness, shortness of breath, fatigue, and fainting. Most side effects are mild to moderate and may improve with continued use or dose adjustment. Patients should report persistent or severe symptoms to their healthcare provider immediately.

MYQORZO is manufactured by Cytokinetics, Inc., a biopharmaceutical company focused on developing innovative cardiac and skeletal muscle therapeutics.

Yes, MYQORZO has been designated as an orphan drug by the FDA. This designation recognizes its development for treating a rare disease—obstructive hypertrophic cardiomyopathy—affecting a limited patient population. Orphan drug status provides regulatory incentives to encourage development of treatments for rare conditions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT